

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for the **general population**. Please read corresponding footnotes for important guidance.

Information for severely immunocompromised individuals, and special populations is located on the following pages.

GENERAL POPULATION						
GROUP	VACCINE	PRIMARY COURSE		VACCINE	BOOSTER	FOURTH DOSE
5 years	Pfizer (COMIRNATY) (Orange) ¹ Moderna (SPIKEVAX) (Blue/Purple) ²	FIRST DOSE	→	SECOND DOSE	Not recommended. ^{11, 12}	
6 – 11 years	Pfizer (COMIRNATY) (Orange) ¹ Moderna (SPIKEVAX) (Red) ³	FIRST DOSE	→	SECOND DOSE	Not recommended. ^{11, 12}	
12 – 15 years	Pfizer (COMIRNATY) (Purple) ⁴ Moderna (SPIKEVAX) (Red) ³ Novavax (NUVAXOVID) ⁵	FIRST DOSE	→	SECOND DOSE	Pfizer (COMIRNATY) (Purple) ⁷ [Novavax (NUVAXOVID)] ⁸	Not recommended. ¹²
16 – 17 years	Pfizer (COMIRNATY) (Purple) ⁴ Moderna (SPIKEVAX) (Red) ³ Novavax (NUVAXOVID) ⁵	FIRST DOSE	→	SECOND DOSE	Pfizer (COMIRNATY) (Purple) ⁷ [Novavax (NUVAXOVID)] ⁸	BOOSTER 3 months after Primary Course. Not approved or recommended.
18 – 29 years	Pfizer (COMIRNATY) (Purple) ⁴ Moderna (SPIKEVAX) (Red) ³ Novavax (NUVAXOVID) ⁵ AstraZeneca (VAXZEVRIA) ⁶	FIRST DOSE	→	SECOND DOSE	Pfizer (COMIRNATY) (Purple) ⁹ Moderna (SPIKEVAX) (Red) ⁹ Novavax (NUVAXOVID) ⁹ AstraZeneca (VAXZEVRIA) ⁹ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁰	BOOSTER 3 months after Primary Course. Not approved or recommended. ¹³
30 – 49 years	Pfizer (COMIRNATY) (Purple) ⁴ Moderna (SPIKEVAX) (Red) ³ Novavax (NUVAXOVID) ⁵ AstraZeneca (VAXZEVRIA) ⁶	FIRST DOSE	→	SECOND DOSE	Pfizer (COMIRNATY) (Purple) ⁹ Moderna (SPIKEVAX) (Red) ⁹ Novavax (NUVAXOVID) ⁹ AstraZeneca (VAXZEVRIA) ⁹ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁰	BOOSTER 3 months after Primary Course. CONSIDER FOURTH DOSE From 3 months after Booster. ¹⁴
50 years+	Pfizer (COMIRNATY) (Purple) ⁴ Moderna (SPIKEVAX) (Red) ³ Novavax (NUVAXOVID) ⁵ AstraZeneca (VAXZEVRIA) ⁶	FIRST DOSE	→	SECOND DOSE	Pfizer (COMIRNATY) (Purple) ⁹ Moderna (SPIKEVAX) (Red) ⁹ Novavax (NUVAXOVID) ⁹ AstraZeneca (VAXZEVRIA) ⁹ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁰	BOOSTER 3 months after Primary Course. FOURTH DOSE From 3 months after Booster.

Notes:

- Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).
- Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
- Moderna (SPIKEVAX) 6 years+ (red cap) vaccine is approved for individuals aged 6 years and older. The multidose vial does not require dilution. The dose for each primary course dose for individuals aged 6 to 11 years is 0.25mL (50µg) and for individuals aged 12 years and older is 0.5mL (100µg) per dose. The dose for booster doses for individuals aged 18 years and older is 0.25mL (50µg).
- Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
- Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg).
- AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL.
- For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
- Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however ATAGI have advised that Novavax (NUVAXOVID) vaccine can be used as a booster in this age group if no other COVID-19 vaccine brand is suitable for that person.
- For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine, Moderna (SPIKEVAX) 6 years+ (red cap) vaccine or Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine are preferred for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to a mRNA vaccine) or for people who do not prefer a mRNA vaccine.
- Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).
- ATAGI does not recommend that a booster dose of COVID-19 vaccine be given to all children aged 5 to 11 years. There is insufficient evidence of severe disease in otherwise healthy children in this age group who have already received two primary doses of a COVID-19 vaccine.
- Booster doses are not currently recommended for children under 15 years who are not at increased risk of severe disease (i.e. severely immunocompromised, have a disability, or have complex and/or multiple health conditions which increase the risk of severe COVID-19) Severe COVID-19 in children is uncommon and the primary course of COVID-19 vaccines generates a strong immune response. The benefit from additional doses of vaccine is likely to be small. Current evidence does not suggest that booster doses are needed at this time.
- At this moment, ATAGI does not support making the fourth dose available to healthy adults aged less than 30 years as it is unclear whether the benefits outweigh the risks in this population.
- People aged 30 to 49 years can receive a second booster dose of a COVID-19 vaccine, but the benefit for people in this age group is less certain. ATAGI encourages people in this age group to have a discussion with their regular medical provider to review their individual health needs and the benefits and risks of a second booster dose.

Detailed information on ATAGI clinical recommendations for COVID-19 vaccines is available at: www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations

Information current as of 7 November 2022

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for individuals with **severe immunocompromise**. Please read corresponding footnotes for important guidance.

Information for the general population, and special populations, is located on separate pages.

SEVERELY IMMUNOCOMPROMISED POPULATIONS							
GROUP	VACCINE	PRIMARY COURSE			VACCINE	FOURTH DOSE	FIFTH DOSE
6 months – 4 years severely immunocompromised. ¹	Moderna (SPIKEVAX) (Blue/Purple) ⁴	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Not approved or recommended.
5 years severely immunocompromised. ^{2,3}	Pfizer (COMIRNATY) (Orange) ⁵ Moderna (SPIKEVAX) (Blue/Purple) ⁴	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Pfizer (COMIRNATY) (Orange) ⁵ FOURTH DOSE 3 months after Primary Course Not approved or recommended.
6 – 11 years severely immunocompromised. ^{2,3}	Pfizer (COMIRNATY) (Orange) ⁵ Moderna (SPIKEVAX) (Red) ⁶	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Pfizer (COMIRNATY) (Orange) ⁵ FOURTH DOSE 3 months after Primary Course Not approved or recommended.
12 – 15 years severely immunocompromised. ²	Pfizer (COMIRNATY) (Purple) ⁷ Moderna (SPIKEVAX) (Red) ⁶ Novavax (NUVAXOVID) ⁸	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Pfizer (COMIRNATY) (Purple) ¹¹ Novavax (NUVAXOVID) ¹² FOURTH DOSE 3 months after Primary Course Not approved or recommended.
16 – 17 years severely immunocompromised. ²	Pfizer (COMIRNATY) (Purple) ⁷ Moderna (SPIKEVAX) (Red) ⁶ Novavax (NUVAXOVID) ⁸	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Pfizer (COMIRNATY) (Purple) ¹¹ Novavax (NUVAXOVID) ¹² FOURTH DOSE 3 months after Primary Course From 3 months after Booster
18 years+ severely immunocompromised. ²	Pfizer (COMIRNATY) (Purple) ⁷ Moderna (SPIKEVAX) (Red) ⁶ Novavax (NUVAXOVID) ⁸ AstraZeneca (VAXZEVRIA) ⁹	FIRST DOSE	→	SECOND DOSE	→	THIRD DOSE 2 months after second dose. ¹⁰	Pfizer (COMIRNATY) (Purple) ¹¹ Moderna (SPIKEVAX) (Red) ⁶ Novavax (NUVAXOVID) ^{12, 13} AstraZeneca (VAXZEVRIA) ¹³ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁴ FOURTH DOSE 3 months after Primary Course. FIFTH DOSE From 3 months after Booster.

Notes:

1. Refer to ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years: <https://www.health.gov.au/news/atagi-recommendations-on-covid-19-vaccine-use-in-children-aged-6-months-to-5-years>
2. Refer to ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised: <https://www.health.gov.au/resources/publications/atagi-recommendations-on-the-use-of-a-third-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised>
3. Refer to ATAGI recommendations for a booster dose of the Pfizer COVID-19 (orange cap) vaccine in children aged 5 to 11 years: <https://www.health.gov.au/news/atagi-recommendations-for-a-booster-dose-of-the-paediatric-pfizer-covid-19-vaccine-in-children-aged-5-to-11-years>
4. Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
5. Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).
6. Moderna (SPIKEVAX) 6 years+ (red cap) vaccine is approved for individuals aged 6 years and older. The multidose vial does not require dilution. The dose for each primary course doses for individuals aged 6 to 11 years is 0.25mL (50µg) and for individuals aged 12 years and older is 0.5 mL (100µg) per dose. The dose for booster doses for individuals aged 18 years and older is 0.25mL (50µg).
7. Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
8. Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg). There is very limited evidence of the efficacy of Novavax in immunocompromised people.
9. AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL. AstraZeneca (VAXZEVRIA) vaccine is not preferred but can be used for the third dose in adults if there are contraindications to mRNA and Novavax (NUVAXOVID) vaccine.
10. The standard interval is 2 months, however ATAGI considers a minimum interval of 4 weeks between the second primary dose and third primary dose to be acceptable for exceptional circumstances (e.g. anticipated intensification of immunosuppression).
11. For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
12. Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however ATAGI have advised that Novavax (NUVAXOVID) vaccine can be used as a booster in this age group if Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is not suitable for that person.
13. For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine, Moderna (SPIKEVAX) 6 years+ (red cap) vaccine or Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine are the preferred vaccines for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to an mRNA vaccine) or for people who do not prefer an mRNA vaccine.
14. Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).

Detailed information on ATAGI clinical recommendations for COVID-19 vaccines is available at: www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations

Information current as of 7 November 2022

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the ATAGI recommendations relating to COVID-19 vaccines for **special populations**. Please read corresponding footnotes for important guidance.

Information for the general population, and for severely immunocompromised individuals, is located on separate pages.

SPECIAL POPULATIONS					
GROUP	VACCINE	PRIMARY COURSE	VACCINE	BOOSTER	FOURTH DOSE
6 months – 4 years with disability, or those who have complex and/or multiple health conditions which increase the risk of severe COVID-19. ¹	Moderna (SPIKEVAX) (Blue/Purple) ⁶	FIRST DOSE → SECOND DOSE		Not approved or recommended.	
5 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. ²	Moderna (SPIKEVAX) (Blue/Purple) ⁶ Pfizer (COMIRNATY) (Orange) ¹⁸	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Orange)	BOOSTER 3 months after Primary Course	Not approved or recommended.
6 – 11 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. ²	Pfizer (COMIRNATY) (Orange) ¹⁸ Moderna (SPIKEVAX) (Red) ⁸	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Orange)	BOOSTER 3 months after Primary Course	Not approved or recommended.
12 – 15 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19. ³	Pfizer (COMIRNATY) (Purple) ⁷ Moderna (SPIKEVAX) (Red) ⁸ Novavax (NUVAXOVID) ⁹	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) ¹⁴ Novavax (NUVAXOVID) ¹⁵	BOOSTER 3 months after Primary Course	Not approved or recommended.
Pregnant, breastfeeding or planning pregnancy. ⁴	Pfizer (COMIRNATY) (Purple) ^{7,11} Moderna (SPIKEVAX) (Red) ^{8,11} Novavax (NUVAXOVID) ^{9,12} AstraZeneca (VAXZEVRIA) ^{10,13}	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) Moderna (SPIKEVAX) (Red) Novavax (NUVAXOVID) ¹⁶ AstraZeneca (VAXZEVRIA) ¹⁶ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁷	BOOSTER 3 months after Primary Course.	Not approved or recommended.
People aged 16+ years who are residents of aged care or disability care facilities, who have complex, chronic or severe conditions that increase their risk of severe COVID-19 illness, or those with disability, significant or complex health needs, or multiple comorbidities which increase the risk of a poor outcome from COVID-19. ⁵	Pfizer (COMIRNATY) (Purple) ⁷ Moderna (SPIKEVAX) (Red) ⁸ Novavax (NUVAXOVID) ⁹ AstraZeneca (VAXZEVRIA) ¹⁰	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY) (Purple) ¹⁴ Moderna (SPIKEVAX) (Red) Novavax (NUVAXOVID) ¹⁶ AstraZeneca (VAXZEVRIA) ¹⁶ Moderna (SPIKEVAX Bivalent) (Blue/Green) ¹⁷	BOOSTER 3 months after Primary Course.	FOURTH DOSE From 3 months after Booster.

Notes:

1. Refer to ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years: <https://www.health.gov.au/news/atagi-recommendations-on-covid-19-vaccine-use-in-children-aged-6-months-to-5-years>
2. Refer to ATAGI recommendations for a booster dose of the Pfizer COVID-19 (orange cap) vaccine in children aged 5 to 11 years: <https://www.health.gov.au/news/atagi-recommendations-for-a-booster-dose-of-the-paediatric-pfizer-covid-19-vaccine-in-children-aged-5-to-11-years>
3. Refer to ATAGI recommendations on first booster dose in adolescents aged 12 to 15 years: <https://www.health.gov.au/news/atagi-recommendations-on-first-booster-dose-in-adolescents-aged-12-15-years>
4. Refer to Pregnancy, breastfeeding and COVID-19 vaccines: <https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/who-can-get-vaccinated/pregnant-women>. Pregnant women aged 30 years and older may receive a second booster dose (a fourth dose) of COVID-19 vaccine. ATAGI does not specifically recommend a second booster dose for healthy adults aged 30 to 49 years but encourages people in this age group to have a discussion with their regular medical provider to review their individual health needs and consider the benefits and risks of a second booster dose.
5. Refer to ATAGI updated recommendations for a fourth dose of COVID-19 vaccine: <https://www.health.gov.au/news/atagi-updated-recommendations-for-a-winter-dose-of-covid-19-vaccine>
6. Moderna (SPIKEVAX) 6 months to 5 years (blue/purple) vaccine is approved for individuals aged 6 months to 5 years. The multidose vial does not require dilution. Each dose is 0.25mL (25µg).
7. Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is approved for individuals aged 12 years and older. Each multidose vial requires dilution with 1.8mL of saline. Each dose is 0.3mL (30µg).
8. Moderna (SPIKEVAX) 6 years+ (red cap) vaccine is approved for individuals aged 6 years and older. The multidose vial does not require dilution. The dose for each primary course doses for individuals aged 6 to 11 years is 0.25mL (50µg) and for individuals aged 12 years and older is 0.5 mL (100µg) per dose. The dose for booster doses for individuals aged 18 years and older is 0.25mL (50µg).
9. Novavax (NUVAXOVID) vaccine is approved for individuals aged 12 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (5µg).
10. AstraZeneca (VAXZEVRIA) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL.
11. mRNA COVID-19 vaccines are the recommended vaccines in pregnancy as there is substantial data on their safe use in pregnancy.
12. Novavax (NUVAXOVID) vaccine can also be used in pregnancy, there is no immunogenicity or safety data for this vaccine in pregnancy but there are no theoretical safety concerns.
13. AstraZeneca (VAXZEVRIA) vaccine is not preferred in pregnancy. Pregnant women who have already received a first dose of AstraZeneca (VAXZEVRIA) vaccine can receive an mRNA COVID-19 vaccine, AstraZeneca (VAXZEVRIA) vaccine, or Novavax (NUVAXOVID) vaccine for their second dose.
14. For people aged 12 to 17 years, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is the only vaccine registered for use as a booster.
15. Novavax (NUVAXOVID) vaccine is not registered by the TGA for use as a booster dose in adolescents aged 12 to 17 years, however ATAGI have advised that Novavax (NUVAXOVID) vaccine can be used as a booster in this age group if Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine is not suitable for that person.
16. For people aged 18 years and older, Pfizer (COMIRNATY) 12 years+ (purple cap) vaccine, Moderna (SPIKEVAX) 6 years+ (red cap) vaccine or Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine are the preferred vaccines for a booster dose, regardless of which vaccine was used for the primary course. Although not preferred, AstraZeneca (VAXZEVRIA) vaccine or Novavax (NUVAXOVID) vaccine can be used as a booster dose in people aged 18 years and older for people who have a contraindication to mRNA vaccines (including those who have had a serious adverse event following mRNA vaccines, such as a history of anaphylaxis or myocarditis attributed to an mRNA vaccine) or for people who do not prefer an mRNA vaccine.
17. Moderna (SPIKEVAX Bivalent) 18 years+ (blue/green) vaccine is approved for individuals aged 18 years and older. The multidose vial does not require dilution. Each dose is 0.5mL (50µg).
18. Pfizer (COMIRNATY) 5-11 years (orange cap) vaccine is approved for individuals aged 5 to 11 years. Each multidose vial requires dilution with 1.3mL of saline. Each dose is 0.2mL (10µg).